Drug Profile
Research programme: cancer therapeutics - ONO Pharmaceutical/Repare Therapeutics
Latest Information Update: 09 Nov 2021
Price :
$50
*
At a glance
- Originator Repare Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Nov 2021 Preclinical trials in Cancer in USA (unspecified route) (Repare Therapeutics pipeline, November 2021)
- 28 Jul 2021 No recent reports of development identified for research development in Cancer in USA
- 08 Mar 2021 Repare Therapeutics announce intention to initiate IND enabling studies in H1 2022